Desmoplastic Melanoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Desmoplastic Melanoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT04897321

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genet…

United States48 participantsStarted 2022-07-06

Treatment: Fludarabine, Cyclophosphamide

All recent trials (6 shown)

Active — Not RecruitingPhase 1

NCT04483778

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid t…

United States68 participantsStarted 2020-07-13

Treatment: second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG

Active — Not RecruitingPhase 2

NCT02775851

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can be removed by surgery (resectable)…

United States57 participantsStarted 2017-02-06

Treatment:

Desmoplastic Melanoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

All recent trials (6 shown)

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

All recent trials (6 shown)

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors